糖尿病及其视网膜病变患者氧化应激状态的评价

目的 观察糖尿病及其视网膜病变患者血清抗氧化酶活性及非酶类抗氧化物、氧化应激代谢产物的水平,探讨氧化应激与糖尿病视网膜病变之间的关系.方法 选择51例2型糖尿病患者,其中糖尿病无并发症者24例(DM组),糖尿病合并视网膜病变者27例(DR组),另选择同期行体检的30例健康者为对照组.收集3组受检者的空腹血清,测定血清抗氧化酶[超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)及过氧化氢酶(CAT)]活性、非酶类抗氧化物[维生素C(V_C)、维生素E(V_E)及还原型谷胱甘肽(GSH)]水平及氧化应激代谢产物[丙二醛(MDA)、共轭二烯(CD)及晚期蛋白质氧化产物(AOPP)]水平.结果 (1)DM组患者血清SOD、GSH-Px、CAT活性分别为(108±14)U/ml、(141±30)U/ml和(5.6±1.6)U/ml;DR组患者分别为(96±13)U/ml、(133±25)U/ml和(5.1±1.4)U/ml;对照组分别为(119±28)U/ml、(156±26)U/ml和(6.8±1.6)U/ml;与对照组比较,DM组及DR组患者血清抗氧化酶活性均显著降低(P＜0.05),且DR组患者SOD活性又显著低于DM组患者(P＜0.05).(2)对照组V_C、V_E、GSH水平分别为(86±26)mg/L、(19.0±5.3)mg/L和(22.0±5.9)μmol/L;DM组患者分别为(64±20)mg/L、(16.6±3.7)mg/L和(20.8±8.2)μmol/L;DR组患者分别为(52±10)mg/L、(16.6±3.7)mg/L和(19.7±5.7)μmol/L;与对照组比较,DM组及DR组患者血清V_C水平均显著降低(P＜0.01),而DR组患者血清V_C水平又显著低于DM组(P＜0.05).(3)对照组血清MDA、CD、AOPP水平分别为(3.1±1.3)μmol/L、(0.32±0.06)和(15.8±4.5)μmol/L;DM组患者分别为(5.4±1.8)μmol/L、(0.43±0.23)和(25.6±7.7)μmol/L;DR组患者分别为(7.9±2.6)μmol/L、(0.57±0.27)和(27.8±7.2)μmol/L;与对照组比较,糖尿病患者氧化应激代谢产物水平显著升高(P＜0.05),且DR组患者血清MDA、CD水平较DM组患者显著升高(P＜0.05).结论 糖尿病及其视网膜病变患者存在着严重的氧化应激,且糖尿病视网膜病变患者氧化应激更严重.     

代谢综合征氧化应激与血清脂联素水平的关系

目的 分析代谢综合征(MS)患者氧化应激状态与血清脂联素水平的关系.方法 依照纳入排除标准收集MS患者126例(MS组),对照组收集年龄性别匹配,血脂、血糖、血压以及肝肾功能正常的健康体检者98例.测定MS组和对照组总脂联素(Total-Ad)、高分子量脂联素(HMW-Ad)以及氧化应激指标[还原型谷胱甘肽(GSH)、氧化型谷胱甘肽(GSSG)和丙二醛(MDA)]的含量.比较对照组和MS组各项指标差异;并用多重线性回归模型分析MS组和对照组中脂联素与氧化应激指标的相关性.结果 MS组与对照组比较,Total-Ad[(3.51±0.83) μg/mL vs (4.34±0.98) μg/mL]、HMW-Ad[(1.32±0.42) μg/mL vs (2.15±0.85) μg/mL]和GSH[(1.15±0.54) μmol/L vs (1.96±0.62) μmol/L]水平降低(P均＜0.01),GSSG[(1.20±0.47) μmol/L vs (0.90±0.23) μmol/L]和MDA[(6.92±1.50) nmol/L vs (4.05±0.65) nmol/L]水平升高(P均＜0.05);在MS组脂联素与各项参数建立的多重线性回归模型中,Total-Ad和HMW-Ad与氧化应激指标中的GSH呈正相关性,偏相关系数分别为0.587和0.480(P＜0.05),与MDA呈负相关性,偏相关系数分别为-0.222和-0.389(P＜0.05).对照组的多重线性回归模型分析得出氧化应激指标与脂联素水平无相关性(P＞0.05).结论 MS患者伴随氧化应激,脂联素与GSH的相关性大于其余氧化应激指标.MS中低脂联素水平和氧化应激密切相关.     

过氧化物酶体增生物激活受体γ在牙龈卟啉单胞菌刺激血管内皮细胞氧化应激中的作用

目的:明确牙龈卟啉单胞菌( Porphyromonas gingivalis, P. gingivalis)刺激人血管内皮细胞时造成氧化应激的损伤程度,探索过氧化物酶体增生物激活受体( peroxisome proliferator-activated receptor, PPAR)γ在此过程的作用. 方法:研究设4组,对照组为人血管内皮细胞系EA. hy926(美国标准生物品收藏中心,美国)加培养基,P. gin-givalis刺激组为P. gingivalis W83刺激EA. hy926细胞,PPARγ激活组为加入PPARγ的激动剂15d-PGJ2 (10 μmol/L)的条件下P. gingivalis 刺激EA. hy926细胞,PPARγ抑制组为加入PPARγ的拮抗剂GW9662(10 μmol/L)的条件下P. gingivalis 刺激EA. hy926细胞,在0、0. 5、1、1. 5、2、4、8、12 h分别留取细胞培养上清液,通过酶联免疫吸附实验检测不同组各时间点培养基中氧化应激产物谷胱甘肽过氧化物酶( glutathione peroxidase ,GSH-PX)、丙二醛( ma-londialdehyde,MDA)浓度,利用荧光探针2 ' ,7 '-二氯荧光素二乙酸酯( 2 ' , 7 '-dichlorofluorescin diacetate, DCFH-DA)检测不同组各时间点细胞内活性氧( reactive oxygen species, ROS)量. 结果:在P. gingivalis刺激组,抗氧化应激的产物GSH-PX(5.56 ±0.97) μmol/L和MDA(0.84 ±0.18) nmol/L较对照组[GSH-PX(4.71 ±0.64) μmol/L, MDA(0.59 ±0.18)nmol/L]显著升高(P<0.05). GSH-PX和MDA水平在PPARγ激活组[GSH-PX(5.38 ±0.84)μmol/L, MDA(0.84 ±0.22) nmol/L]与抑制组[GSH-PX(5.37 ±0.76) μmol/L, MDA(0.85 ±0.14) nmol/L]显著高于对照组(P<0. 05). PPARγ激活组,GSH-PX水平在0. 5和8 h显著高于1. 5至4 h水平(P<0. 05),MDA水平各时间点差异无统计学意义. PPARγ抑制组,各时间点GSH-PX和MDA水平差异无统计学意义. P. gingivalis刺激组细胞内的活性氧水平显著高于对照组(10 108. 65 ± 1 805. 18 vs. 6 049. 06 ± 1 199. 19,P<0. 05),PPARγ激活组(7 120. 94 ± 1 447. 30)和PPARγ抑制组(6 727. 35 ± 1 483. 68)细胞内的活性氧水平与对照组差异无统计学意义. 结论:P. gingivalis刺激人血管内皮细胞可引起氧化应激反应,PPARγ参与调节此过程.     

持续气道正压通气治疗对阻塞性睡眠呼吸暂停综合征患者体内SOD、GSH-PX 和MDA水平的影响

目的 研究持续气道正压通气(CPAP)后阻塞性睡眠呼吸暂停综合征(OSAS)患者体内超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-PX)活力和丙二醛(MDA)含量的变化.方法 选择OSAS患者52例行SOD、GSH-PX活性和血清MDA含量检测;对OSAS患者行持续气道正压通气治疗3个月后,重新检测SOD、GSH-PX和血清MDA含量,并选择50例健康人作为正常对照.结果 SOD、GSH-PX活性和血清MDA含量,正常对照组分别为(94.15±12.53) U/ml、(148.36±12.24)mIU/ml、(7.87±2.82)nmol/ml;OSAS患者含量分别为(69.48±10.79)U/ml、(110.04±11.89)mIU/ml、(20.17±2.57)nmol/ml;持续正压通气(CPAP)治疗3个月后,OSAS患者的SOD、GSH-PX活性和血清MDA含量分别为(90.36±13.19)U/ml、(146.63±14.54)mIU/ml、(8.21±2.73)nmol/ml,与正常对照组相比,OSAS患者MDA明显升高,SOD、GSH-PX活性显著降低,差异均有统计学意义(P<0.01);CPAP治疗3个月后,OSAS患者的SOD、GSH-PX活性、MDA含量与正常对照组相比差异无统计学意义(P>0.05).结论 OSAS患者体内存在严重的氧自由基代谢失衡,CPAP治疗3个月后,氧自由基代谢可基本恢复正常.     

维生素E对小鼠日本血吸虫病肝纤维化的治疗作用及其机制

目的: 探讨维生素E (Vit E)抗小鼠日本血吸虫病肝纤维化作用及其机制. 方法: 用日本血吸虫尾蚴皮肤敷贴法感染小鼠,构建日本血吸虫病肝纤维化模型,以肝纤维化达Ⅱ级或Ⅱ级以上作为开始Vit E治疗标志. 实验分5组: 正常对照组、模型组及Vit E高、中、低剂量组(每日150, 50, 5 mg/kg), 8 wk末处死动物,HE和VG染色对肝组织进行病理学检查,分光光度法检测肝组织丙二醛(MDA)含量和超氧化物歧化酶(SOD)活性,免疫组化SP法检测肝星状细胞(HSC)标记物α-平滑肌动蛋白(α-SMA)表达,RT-PCR方法检测肝脏α1(I)型前胶原mRNA表达. 结果: Vit E降低模型组肝脏MDA含量[(5.00±0.31) μmol/g vs (11.66±1.84) μmol/g, P＜0.05],提高SOD活性[(249.84±26.22) μkat/g vs (120.11±42.61) μkat/g, P＜0.05];减少α-SMA阳性表达 [(0.41±0.02) vs (0.68±0.02), P＜0.05];降低肝脏胶原含量[(0.23±0.01) vs (0.60±0.11), P＜0.05]和α1(I)型前胶原基因表达[(0.28±0.01) vs (0.85±0.15), P＜0.05]. 结论: Vit E具有抗小鼠日本血吸虫病肝纤维化作用,其机制与抗脂质过氧化作用、抑制HSC活化和增殖、降低α1(I)型前胶原基因表达和胶原合成有关.     

老年重症患者术中应用自由基清除剂依达拉奉的多中心疗效分析

目的 观察老年重症患者手术中应用依达拉奉对预后的影响.方法 2008年7月1日至9月30日在北京朝阳医院、北京同仁医院、北京安贞医院和卫生部北京医院4家医院的400例老年重症手术患者按随机数字表法分为试验组与对照组,各200例.麻醉开始前试验组患者静脉泵入依达拉奉(60mg/40 ml)直至手术结束,对照组以等量生理盐水代替.分别于桡动脉穿刺后、手术开始后1 h及缝皮前检测超氧化物歧化酶(SOD)与丙二醛水平,记录术中情况及术后病死率、总住院日、重症监护病房(ICU)停留时间、术后机械通气时间与术后并发症情况.其中行不停跳冠状动脉旁路移植术患者于术前和术后24 h检查肌钙蛋白Ⅰ(cTn Ⅰ)与左室射血分数(LVEF).结果 试验组手术开始后1 h与缝皮前SOD水平均高于对照组[(87±14)U/ml比(78±14)U/ml,(83±13)U/ml比(77±14)U/ml,P＜0.01、＜0.05];丙二醛则均低于对照组[(11±5)nmol/L比(14±7)nmol/L,(11±5)nmol/L比(14±6)nmol/L,P＜0.05、＜0.01].术中低血压需持续应用血管活性药物支持者对照组多于试验组(37例比19例,P＜0.01),试验组总住院日、ICU住院日都短于对照组[(21±9)d比(23±9)d,(10±7)d比(13±9)d,均P＜0.05],行不停跳冠状动脉旁路移植术患者试验组术后cTn Ⅰ和LVEF与术前和对照组相比差异均有统计学意义(均P＜0.05).结论 老年重症患者术中应用依达拉奉可防止丙二醛升高、SOD下降,降低术中低血压发生率,减少老年重症患者总住院日与ICU住院日.特别是行不停跳冠状动脉旁路移植术患者术中应用依达拉奉,术后cTn Ⅰ与LVEF测量值试验组与术前和对照组相比都有明显改善.

Abstract：

Objective To observe the effects of intraoperative application of radical scavenger edaravone in severe elderly cases. Methods A total of 400 severe elderly patients scheduled for surgery were randomly assigned to receive edaravone 60 mg/40 ml ( Group Y) or an equal volume of normal saline (Group C). The arterial blood samples were harvested at immediately after pricking, 1 hour after the beginning of surgery and before saturation to determine the levels of superoxide dismutase (SOD) and malondialdehyde (MDA). The operative duration, fluid volume, blood loss, blood transfusion volume,urine output, intraoperative adverse events, mortality rate, total hospital stay, intensive care unit (ICU)stay, postoperative mechanical ventilation time and complications were recorded. Patients undergoing offpump coronary artery bypass graft (OPCABG) were evaluated for troponin Ⅰ (cTn Ⅰ ) and left ventricular ejection fraction (LVEF) before and after 24 hours of surgery. Results SOD was higher and MDA lower in Group Y than those in Group C at 1 hour intraoperation and before saturation[SOD: (87 ± 14)U/ml vs(78 ±14)U/ml, (83±13)U/mlvs(77±14)U/ml, P＜0.01, ＜0.05; MDA : (11 ±5)nmol/Lvs(14±7)nmol/L,( 11 ± 5 ) nmol/L vs ( 14 ± 6) nmol/L, P ＜ 0. 05, ＜ 0. 01]. There were more intraoperative hypotension cases requiring a continuous application of vasoactive drugs in Group C(37 cases vs 19 cases),total hospital stay[(21 ±9 )d vs (23±g)d, P＜0.05] and ICU stay[(10±7)dvs (13±9)d, P＜0. 05] were also longer. Postoperative cTn Ⅰ and LVEF of Group Y significantly improved in OPCABG cases ( all P ＜ 0. 05 ). Conclusion The intraoperative application of edaravone in severe elderly patients may prevent MDA increase and SOD decrease and reduce free radical damage. Especially in OPCABG patients,cTn Ⅰ and LVEF improve significantly.     

(英文)肾移植患者血清非对称二甲基精氨酸水平变化与内皮功能改善的关系

目的:探讨肾移植前后慢性肾衰患者血清非对称二甲基精氨酸(ADMA)水平变化与内皮功能改善的关系.方法:选择首次接受同种异体肾移植术患者38例和健康对照者36例.分别于移植术前、移植术后第1,3,7,14及28天抽血分离血清,高效液相色谱法(HPLC)检测血清ADMA和SDMA水平,硝酸还原酶比色法检测血清NO活性,DTNB法测定全血硒谷胱甘肽过氧化物酶 (SeGSHPx)活性,,硫代巴比妥酸法测定血清丙二醛(MDA)水平,ELISA法检测血清C反应蛋白(CRP)水平;移植术前及术后第28天多普勒超声法检测肱动脉内皮依赖性血管舒张功能(FMD).结果:肾移植术前患者血清ADMA[(2.36±0.89) μmol/L],SDMA[(0.48±0.11) μmol/L],MDA[(7.24±1.07) μmol/L]及CRP水平[9.24(0.42～66.24) μmol/L]明显高于年龄匹配的正常对照组[ADMA:(0.49±0.12) μmol/L;SDMA:(0.24±0.08) μmol/L;MDA:(3.12±1.21) μmol/L;CRP:2.52(0.24～5.94) μmol/L, 均P＜0.01],血清NO[(38.48±12.36) μmol/L] 及SeGSHPx[(104.23±14.46) U/L]活性、FMD(5.43%±1.87%)明显低于正常对照组 [NO:(70.13±12.46) μmol/L;SeGSHPx:(201.36±82.35) U/L;FMD:(10.11±1.64)%,均P＜0.01].移植术后第1天开始血清ADMA[(1.97±0.76) μmol/L],SDMA[(0.43±0.06) μmol/L],MDA[(6.24±0.82) μmol/L]及CRP[8.32(0.46～33.42) μmol/L]水平明显下降而血清NO[(42.63±11.32) μmol/L],SeGSHPx[(116.23±17.24) U/L]活性明显增高,第28天时除SDMA水平与对照组无差别外(P＞0.05),其余指标仍高于或低于正常对照组(P＜0.05).第28天时FMD(7.04±2.13)%较移植前明显增高但仍低于正常时对照组(P＜0.05).移植前后血清ADMA水平与MDA呈正相关,与SeGSHPx及FMD呈负相关.结论:慢性肾衰患者移植前后血清ADMA水平变化与内皮功能异常关系密切,并与氧化应激程度相关.     

半叶马尾藻多糖体内抗肿瘤作用及其机制探讨

目的研究半叶马尾藻(SC)多糖体内抗肿瘤作用及其机制。方法观察SC多糖对S180小鼠瘤质(重)量、胸腺等免疫器官的影响及分别测定小鼠血清中超氧化物歧化酶(SOD),谷胱甘肽过氧化物酶(GSH-PX),丙二醛(MDA)的活性。结果SP可明显抑制S180小鼠瘤体的生长,腹腔注射SC150 mg/kg·b.w.,连续注射10 d,可使肿瘤抑制率达63.52%;小鼠血清中SOD、GSH-PX的活性分别由(350.76±31.34)NU/ml,(299.36±43.63)U增加到(487.76±16.67)NU/ml(P<0.01),(370.90±16.49)U(P<0.01);MDA由(9.46±1.77)nmol/ml降至(7.26±1.18)nmol/ml(P<0.05)。结论SC多糖可通过提高机体免疫功能和抗氧化能力从而抑制肿瘤的生长。     

还原型谷胱甘肽联合前列腺素E1治疗慢性乙型肝炎疗效分析

目的 探讨还原型谷胱甘肽(GSH)联合前列腺素E1治疗慢性乙型肝炎(慢性乙肝)患者的疗效及对患者体内氧化损伤的影响.方法 将我院2007年1月-2009年1月收治的62例慢性乙肝患者随机分为观察组(31例)和对照组(31例),在支持治疗的基础上,对照组给予GSH 1 200 mg加入100 ml 0.9%氯化钠溶液中静脉滴注,1次/d;观察组在对照组治疗的基础上,给予前列腺素E1 20 μg加入100 ml 0.9%氯化钠溶液中静脉滴注,1次/d.均治疗4周.比较两组患者治疗后的临床疗效及治疗前后血清超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、丙二醛(MDA)水平.结果 治疗后治疗组显效22例,有效7例,无效2例;对照组显效17例,有效5例,无效9例,两组患者疗效间差异有统计学意义(u=1.99,P＜0.05).治疗前对照组患者血清SOD、GSH-Px、MDA水平[分别为(106±18)μU/L、(57.8±23.4)U/L和(9.4±1.3)μmol/L]与观察组[分别为(103±13)μU /L、(57.4±21.4)U/L和(9.4±1.3)μmol/L]比较,差异均无统计学意义(P＞0.05);治疗后对照组患者血清SOD、GSH-Px、MDA水平[分别为(173±13)μU/L、(89.4±15.8)U/L和(7.9±3.5)μmol/L]与观察组[分别为(199±11)μU/L、(103.2±14.3)U/L和(5.6±2.4)μmol/L]比较,差异均有统计学意义(P＜0.05).结论 GSH联合前列腺素E1治疗慢性乙肝患者的疗效优于单用GSH治疗者,联合治疗能改善慢性乙肝患者体内的氧化-抗氧化损伤平衡的紊乱.     

肺表面活性物质对哮喘大鼠血清一氧化氮、丙二醛含量及超氧化物歧化酶活性的影响

目的　观察肺表面活性物质 (PS)对大鼠哮喘模型中一氧化氮 (NO)、丙二醛 (MDA)含量及超氧化物歧化酶 (SOD)活性的变化 ,探讨PS治疗哮喘的机制。方法　设立正常组、哮喘组、生理盐水 (NS)处理组及PS处理组 ,建立大鼠哮喘模型 ,检测血清中NO-2 /NO-3 、MDA含量及SOD活性。结果　正常大鼠的血清NO-2 /NO-3 、MDA及SOD分别为 (10 6 73± 34 96 ) μmol/L、(17 79±5 6 8)nmol/mL、(81 80± 7 93)U/mL ;哮喘组分别为 (410 2 3± 86 77) μmol/L、(32 4 2± 6 11)nmol/mL、(34 72± 12 95 )U/mL ;NS处理组分别为 (45 2 86± 85 2 7) μmol/L、(34 0 8± 7 83)nmol/mL、(2 8 89±13 19)U/mL ;PS处理组分别为 (2 70 19± 82 0 9) μmol/L、(2 6 2 4± 5 92 )nmol/mL、(78 5 2± 7 11)U/mL。哮喘组血清中NO-2 /NO-3 和MDA含量高于正常组 (P <0 0 1) ,SOD活性低于正常组 (P <0 0 1) ;NS处理组与哮喘组比较各项指标均无显著性差异 (P >0 0 5 ) ;PS处理组血清SOD活力明显高于哮喘组 (P <0 0 1) ;NO-2 /NO-3 和MDA含量显著低于哮喘组 (P <0 0 1) ;PS处理组NO-2 /NO-3 和MDA含量显著高于正常组 (P <0 0 1) ,SOD活性与正常组比较无显著性差异 (P >0 0 5 )。结论　PS干预可影响哮喘大鼠体内氧化 /抗     

Acupuncture Treatment of Vomiting

CASE HISTORY A female patient, 46 years old, head of the foreign affairs department of a certain university in Beijing, paid her first visit on October 9, 2006, with the chief complaint of vomiting for one month. She got vomiting after meals in early September. Before that, she had discomfortable sensation in the stomach due to angry with others, but she didn't pay much attention. Later, it developed into vomiting after eating. After the vomiting, the discomfort would be relieved, but with slight hypodynamia. She was once diagnosed as having 'neurogenic vomiting'. Having taken some western and Chinese drugs, the above symptoms were a little bit improved, but she would have nausea upon eating and with regurgitation. Because of the fear for vomiting, she did not dare to have food intake, with body weight reduction of 6 kilos in one month.     

Qiu Baoguo''''s Experience in Treating Consumptive Syndromes after Radio-Chemotherapies

Radiotherapy and chemotherapy are the important modern medical therapies for malignant tumors,yet they can also bring about serious local and systemic toxic side reactions so to decrease the patient;'s life quality,manifested by a series of consumptive symptoms.Having engaged in the combined work of Chinese and western medicine for nearly 50 years,the research fellow Qiu Baoguo in Henan Provincial Academy of TCM has developed his unique views on the TCM study of consumptive syndromes.The author of this essay had once the fortune tO follow Dr.Qiu in clinic,and specially would like to introduce in the following Dr.Qiu's experience in treating consumptive syndromes after radio-chemotherapies for patients with malignant tumor.     

Insomnia Due to Deficiency of Both the Heart and Spleen Treated by Acupuncture-Moxibustion and Chinese Tuina

OBJECTIVE: To observe therapeutic effects of the comprehensive therapy of acupuncture-moxibustion and Chinese Tuina for treatment of insomnia due to deficiency of both the heart and spleen. METHODS: 92 cases were divided randomly into the treatment group (treated by acupuncture-moxibustion and Chinese Tuina) and the control group (treated by acupuncture-moxibustion). RESULTS: The therapeutic effect of the treatment group was obviously superior to that of the control group (the CHI2 test showed P < 0.01). CONCLUSIONS: The comprehensive therapy of acupuncture-moxibustion and Chinese Tuina can give marked therapeutic effects for treatment of insomnia due to deficiency of both the heart and spleen.     

Analysis of CK-19,PDX-1,Nestin,Ngn3 in different donor islet purity in rats

Objective: To investigate if there are the CK-19, PDX-1, Nestin, Ngn3 positive cells in the donor islets of different purity in rats. Methods: Thirty male adult SD rats were randomly divided into 3 groups. Islets were isolated using digestion by ductal injection of collagenase. Group Ⅰ (n=10): Separating cell preparations were not purified, Group Ⅱ(n=10): Islet sediment was purified with 25% Ficoll400 ,Group Ⅲ (n=10): Islet sediment was purified with 25% and 11% Ficoll-400. The levels of protein of CK-19, PDX-1, Nestin and Ngn3 were detected by immunohistochemistry and the mRNA of CK-19, PDX-1, Nestin, Ngn3 was amplified by RT-PCR. Results: After two different purification methods applied, three islet preparations of different purities were obtained. The difference of islet purity was significant among various groups (P＜0.05). Compared with group Ⅱ and group Ⅲ,the protein and mRNA of CK-19, PDX-1, Nestin,Ngn3 were both higher in group Ⅰ; group Ⅲ was poorly expressed. Conclusions: The three different islet purity donor islet have different CK-19, PDX-1, Nestin, Ngn3 positive cells within them, indicating that there are some islet stem cells in the purified donor islet.     

A preliminary screening study on the associated proteins in human psoriasis vulgaris by serum proteomics technologies

Objective：To investigate the optimum screening conditions of associated proteins in human psoriasis vulgaris by serum proteomics technique, and to screen the different expression proteins related with psoriasis vulgaris. Methods：Serum samples of peripheral blood were collected from newly diagnosed psoriasis vulgaris patients in the clinic, and 20 matched healthy persons. Serum albumin IgG was removed by filtering with ProteoExtract Albumin/IgG. After comparative proteomics analysis the different protein spots were identified using 2-DE and MS. Results ：Electrophoresis figures with high resolution and reproducibility were obtained. Three different expression proteins were found only in the serum from psoriasis vulgaris patients, while nine other different proteins expressing from healthy volunteers. Conclusion：The protein expression was different in the serum between the psoriasis vulgaris patients and healthy volunteers. It was hoped that we could find the biomarkers related to psoriasis vulgaris by using proteomics.     

A CASE OF HUGE GASTRIC DISOPYROBEZOAR

PYTOBEZOARS are common bezoars in gastrontestinal tract, commonly seen in stomach and mall intestine,1but huge disopyrobezoars are     

Acupuncture Treatment of Chest Bi Syndrome

CASE HISTORY A male,a retired officer of 61 years old,paid his first visit on May 12,2006.The patient stated that 2 weeks before he suddenly got paroxysmal precordial choking pain,with irregular attacks.Each attack would last several seconds to several minutes.The attack was accompanied with heavy oppressed sensation in the precordial region,palpitation,lassitude,and in severe cases,sweating,which was once diagnosed by a hospital as'coronary heart disease'.Recalling the case history,the patient said that several days before he got angry with others because of some affairs in work,and he was not so used to the life pattern since he had just retired from his busy working post.At usual times,he was quick tempered and peevish.In recent days,he had poor appetite,and loose stool.     

Instructions to Contributors

The English edition of Chinese Journal of Integrative Medicine is edited and published by the Chinese Journal of Integrated Traditional and Western Medicine Press.Original scientific papers of advanced clinical and experimental medicine in the field of complementary/alternative medicine or integrative medicine are expected.